Supercharged immune cells take on hard-to-treat melanoma in early trial

This early-phase study tests a new type of cell therapy for people with advanced melanoma that has not responded to standard treatments. The therapy uses a patient's own immune cells (NK cells) that are engineered in the lab to recognize and attack a protein called PRAME found on melanoma cells. The main goal is to find the safest dose and see if the treatment can control the disease.